$EMBC

Mann Jeffrey Z purchased $100K of EMBC

Mann Jeffrey Z (Pres, Pharm Svc&Prod Mgmt, CLO) purchased 20,000 shares of Embecta Corp. (EMBC) at $4.99 on 2026-08-12.

Original reporting
SEC EDGAR · Mann Jeffrey Z
Published Aug 13, 2026, 2:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 2:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EMBC
Bullish
medium confidence
Mentioned
$EMBC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EMBCBullishLow
01

Why it matters

The newest fact is the officer’s open-market purchase of 20,000 shares at $4.9900 on 2026-08-12, filed on 2026-08-13.

02

Market read

Traders may note the insider buy as a small sentiment input, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide context on prior holdings changes or company fundamentals.

Relevance 4/10Novelty 5/10Timing: filed 2026-08-13, transaction dated 2026-08-12

Background

This is an SEC Form 4 insider transaction disclosure for Embecta Corp. (EMBC).

Company-level read

Ticker impact

$EMBCBullishMedium confidence
Context

Embecta insider Jeffrey Z Mann bought 20,000 shares on 2026-08-12 at $4.9900, totaling $99,800, per Form 4.

Expected impact

Low likelihood of a sustained move; any reaction is likely limited and short-lived.

Evidence & confidence

The filing is primary-source and time-stamped, but it is an insider buy without a 10b5-1 plan and without accompanying guidance, contracts, or earnings data.

Market effects

No direct sector read-through; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

Insider purchases can be driven by diversification, liquidity needs, or routine compensation-related activity, so the signal may be weaker than it appears.

Key entities

  • Embecta Corp.

    Subject of the Form 4 insider transaction disclosure.

  • Mann Jeffrey Z

    President, Pharm Svc and Product Management, CLO, reported an open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EMBCMedAI 8/10

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Embecta (NASDAQ:EMBC) held its FY2026 Q3 earnings call. Revenue was $271.7M, down 8.1% YoY, with U.S. revenue down 24.6% and international up 11.5% on Owen Mumford strength. Adjusted EPS was $0.56. Free cash flow was $41M. FY2026 guidance: revenue $1.015B-$1.035B, adjusted EPS $1.80-$1.90, margin 23.5%-24%.

$EMBCHighAI 9/10

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Embecta (EMBC) reported Q3 FY2026 revenue of $271.7 million, down 8.1% YoY, with U.S. revenue down 24.6% and international revenue up 11.5%. Adjusted EPS was $0.56. The company raised FY2026 adjusted operating margin guidance to 23.5% to 24% and EPS to $1.80 to $1.90, reaffirming revenue guidance of $1.015B to $1.035B.

$EMBCMed

EMBC Investor Announcement: Embecta Sued on behalf of Investors to Recover Losses after Insulin Pen Issues Lead to 57% Stock Drop

Bleichmar Fonti & Auld LLP said it filed a securities fraud class action against Embecta Corp. (NASDAQ:EMBC) and executives, alleging misleading statements about the strength of its insulin pen needle category. The suit cites a May 5, 2026 stock drop of 57.8% after Q2 results missed guidance, and notes a lead plaintiff deadline of Aug. 17, 2026.

$EMBCMed

Embecta Corp. (EMBC): Results of Operations and Financial Condition

Embecta Corp. (EMBC) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results PARSIPPANY, N.J., Aug 7, 2026 (GLOBE NEWSWIRE) – Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and n

$EMBCMed

$EMBC Notification: Embecta Accused of Misrepresentations about its Insulin Pen Issues in Securities Fraud Class Action

Bleichmar Fonti & Auld LLP said a securities-fraud class action was filed against Embecta Corp. (NASDAQ:EMBC) and executives, alleging misstatements about the strength of its insulin pen needle category. The suit follows Embecta’s May 5, 2026 stock drop of 57.8% after Q2 results missed guidance; the firm cites a dividend cut from $0.15 to $0.01. Lead plaintiff deadline: Aug. 17, 2026.